Clinical Trial Update: Ikervis for DED Due to GVHD Post Allo-HSCT [Phase 4]

View source ↗

Summary

Clinical trial update for Ikervis in DED due to GVHD after allogeneic stem cell transplant (Phase 4) with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Syndrome with Excess Blasts-1

Drugs mentioned

• Ikervis (ciclosporin ophthalmic emulsion)

Snippet

Sponsor: Singapore Eye Research Institute | Conditions: Leukemia (Both ALL and AML), MDS-EB-1 | Phase 4 | Status: UNKNOWN